Smith & Nephew plc (LON:SN) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Smith & Nephew plc (LON:SN – Get Free Report) have earned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 1,340.11.

A number of equities analysts have issued reports on SN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,400 price objective on shares of Smith & Nephew in a report on Thursday, June 11th. Shore Capital Group reiterated a “buy” rating and issued a GBX 1,000 target price on shares of Smith & Nephew in a report on Tuesday, July 21st. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,350 price target on shares of Smith & Nephew in a research report on Monday, June 29th. UBS Group restated a “neutral” rating and set a GBX 1,300 price target on shares of Smith & Nephew in a report on Tuesday, May 5th. Finally, Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a research report on Friday, July 10th.

Get Smith & Nephew alerts:

View Our Latest Report on Smith & Nephew

Smith & Nephew Stock Up 1.9%

Shares of Smith & Nephew stock opened at GBX 1,162 on Tuesday. The stock has a market capitalization of £12.74 billion, a P/E ratio of 41.84, a PEG ratio of 0.46 and a beta of 0.68. The business has a 50 day moving average of GBX 1,131.28 and a 200 day moving average of GBX 1,197.36. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90.

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.

Featured Stories

• Five stocks we like better than Smith & Nephew
• AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
• Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
• Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
• Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.